Peter A. Hruskoci

Array ( [id] => 14102347 [patent_doc_number] => 20190092849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES [patent_app_type] => utility [patent_app_number] => 16/070385 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16070385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943294 [patent_doc_number] => 20170247444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES' [patent_app_type] => utility [patent_app_number] => 15/421473 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 59835 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15421473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11647903 [patent_doc_number] => 20170143804 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'Use of Ultrarapid Acting Insulin' [patent_app_type] => utility [patent_app_number] => 15/421743 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 28509 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15421743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12052553 [patent_doc_number] => 20170328897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'METHODS OF PREDICTING RESPONSE TO TREATMENT WITH ANTI-TNFalpha BIOLOGICAL INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/421094 [patent_app_country] => US [patent_app_date] => 2017-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15177 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15421094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14326587 [patent_doc_number] => 10294297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Methods for treatment using anti-NMU agents [patent_app_type] => utility [patent_app_number] => 15/418550 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 84 [patent_no_of_words] => 27463 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117317 [patent_doc_number] => 20180000902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'PREVENTION OF HYPOGLYCAEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS' [patent_app_type] => utility [patent_app_number] => 15/411557 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24910 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13824061 [patent_doc_number] => 20190015515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => GLUCOSE RESPONSIVE INSULIN DELIVERY COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/070223 [patent_app_country] => US [patent_app_date] => 2017-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16070223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16769774 [patent_doc_number] => 10980857 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Treatment with GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis [patent_app_type] => utility [patent_app_number] => 16/068463 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5509 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092538 [patent_doc_number] => 20170349631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/400831 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 43265 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13778077 [patent_doc_number] => 20190002577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies [patent_app_type] => utility [patent_app_number] => 16/068218 [patent_app_country] => US [patent_app_date] => 2017-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572165 [patent_doc_number] => 10894076 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof [patent_app_type] => utility [patent_app_number] => 16/066586 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 40 [patent_no_of_words] => 14787 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971218 [patent_doc_number] => 20170275370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS' [patent_app_type] => utility [patent_app_number] => 15/387542 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 93 [patent_figures_cnt] => 93 [patent_no_of_words] => 79100 [patent_no_of_claims] => 70 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15387542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554213 [patent_doc_number] => 20170100459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE' [patent_app_type] => utility [patent_app_number] => 15/383730 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 24458 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15383730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11628778 [patent_doc_number] => 20170138967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'METABOLICS BIOMARKER FOR NAFLD AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/356050 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10152 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15356050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11625903 [patent_doc_number] => 20170136092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE' [patent_app_type] => utility [patent_app_number] => 15/355386 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 10152 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13011959 [patent_doc_number] => 10029080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-24 [patent_title] => Method for delivering exenatide into a lumen of the intestinal tract using a swallowable drug delivery device [patent_app_type] => utility [patent_app_number] => 15/339722 [patent_app_country] => US [patent_app_date] => 2016-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 53 [patent_no_of_words] => 23822 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15339722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757514 [patent_doc_number] => 20170204382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'ISOLATED GDF TRAP POLYPEPTIDE' [patent_app_type] => utility [patent_app_number] => 15/336363 [patent_app_country] => US [patent_app_date] => 2016-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 29568 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15336363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13887801 [patent_doc_number] => 10196441 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Compositions and methods for treating fatty tissue buildup [patent_app_type] => utility [patent_app_number] => 15/334616 [patent_app_country] => US [patent_app_date] => 2016-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 14164 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15334616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11684096 [patent_doc_number] => 09682127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-20 [patent_title] => 'Osmotic delivery device comprising an insulinotropic peptide and uses thereof' [patent_app_type] => utility [patent_app_number] => 15/291523 [patent_app_country] => US [patent_app_date] => 2016-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 12810 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15291523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436097 [patent_doc_number] => 20170037117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/290869 [patent_app_country] => US [patent_app_date] => 2016-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 59933 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15290869 [rel_patent_id] =>[rel_patent_doc_number] =>)